Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study

Keyphrases

• Antiretroviral Therapy 100%
• HIV-associated Neurocognitive Disorders 100%
• Effect Study 100%
• Group Studies 100%
• Genome-wide Association Study 100%
• Global Deficit Score 100%
• SNP 18%
• Significant SNPs 18%
• HIV Infection 9%
• Comorbidity 9%
• Psychosocial Outcomes 9%
• T Cell Receptor 9%
• Neurocognitive Impairment 9%
• Cognitive Impairment 9%
• Neurocognitive 9%
• Functional Impairment 9%
• Affymetrix 9%
• Association Test 9%
• Biologically Plausible 9%
• Combined Antiretroviral Therapy (cART) 9%
• Performance-based 9%
• Multivariable Logistic Regression 9%
• Chromosome 2 9%
• Chromosome 14 9%
• Multivariate Linear Regression 9%
• SNP Array 9%
• Significance Threshold 9%
• Genotype Data 9%
• Genome-wide Significance 9%
• Regression-based Method 9%
• Host Genomics 9%
• FraSCAti 9%

Neuroscience

• Human Immunodeficiency Virus 100%
• HIV Associated Dementia 100%
• Genome-Wide Association Study 100%
• Cognitive Disorders 12%
• Chromosome 2 12%
• Chromosome 14 12%
• T Lymphocyte Receptor 12%
• Comorbidity 12%

Biochemistry, Genetics and Molecular Biology

• Human Immunodeficiency Virus 100%
• Genome-Wide Association Study 100%
• Single Nucleotide Polymorphism 36%
• Genotyping 9%
• Self Report 9%
• Chromosome 2 9%
• T Cell Receptor 9%
• Chromosome 14 9%
• SNP Array 9%
• Comorbidity 9%
• Genomics 9%